The European Medicines Agency is moving forward with plans to restructure the organization. EMA’s management team began transitioning to a new structure on August 1, 2013. The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.
EMA will announce details of the new structure of the organization in September 2013.
Source: European Medicines Agency